Search

Your search keyword '"Fätkenheuer, Gerd"' showing total 631 results

Search Constraints

Start Over You searched for: Author "Fätkenheuer, Gerd" Remove constraint Author: "Fätkenheuer, Gerd" Language english Remove constraint Language: english
631 results on '"Fätkenheuer, Gerd"'

Search Results

1. Infektiologie in der stationären Versorgung in Deutschland: Positionspapier der Deutschen Gesellschaft für Infektiologie (DGI)

2. Incidence and risk factors for HIV-tuberculosis coinfection in the Cologne–Bonn region: a retrospective cohort study

4. All-cause and AIDS-related mortality among people with HIV across Europe from 2001 to 2020: impact of antiretroviral therapy, tuberculosis and regional differences in a multicentre cohort study

5. Dynamics and durability of HIV-1 neutralization are determined by viral replication

6. Early trajectories of virological and immunological biomarkers and clinical outcomes in patients admitted to hospital for COVID-19: an international, prospective cohort study

8. Efficacy and safety of an early oral switch in low-risk Staphylococcus aureus bloodstream infection (SABATO): an international, open-label, parallel-group, randomised, controlled, non-inferiority trial

9. Safety and efficacy of doravirine as first-line therapy in adults with HIV-1: week 192 results from the open-label extensions of the DRIVE-FORWARD and DRIVE-AHEAD phase 3 trials

10. Implementing the Lolli-Method and pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools: a pilot project

11. Discovery of highly neutralizing human antibodies targeting Pseudomonas aeruginosa

12. Influence of UGT1A1 and SLC22A6 polymorphisms on the population pharmacokinetics and pharmacodynamics of raltegravir in HIV-infected adults: a NEAT001/ANRS143 sub-study

13. Results of the Cologne Corona surveillance (CoCoS) study – a prospective population-based cohort study: incidence data and potential underestimation of new SARS-CoV-2 adult infections by health authorities

14. Effective high-throughput RT-qPCR screening for SARS-CoV-2 infections in children

15. Efficacy and safety of two neutralising monoclonal antibody therapies, sotrovimab and BRII-196 plus BRII-198, for adults hospitalised with COVID-19 (TICO): a randomised controlled trial

16. Pooled RT-qPCR testing for SARS-CoV-2 surveillance in schools - a cluster randomised trial

19. Torque Teno Virus Load Is Associated With Centers for Disease Control and Prevention Stage and CD4+ Cell Count in People Living With Human Immunodeficiency Virus but Seems Unrelated to AIDS-Defining Events and Human Pegivirus Load.

21. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 96-week results of a randomised, double-blind, non-inferiority, phase 3 trial

25. Long‐lived macrophage reprogramming drives spike protein‐mediated inflammasome activation in COVID‐19

27. Doravirine versus ritonavir-boosted darunavir in antiretroviral-naive adults with HIV-1 (DRIVE-FORWARD): 48-week results of a randomised, double-blind, phase 3, non-inferiority trial

28. Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study

35. Treatment of Early Syphilis

38. Topical azithromycin for the prevention of Lyme borreliosis: a randomised, placebo-controlled, phase 3 efficacy trial

39. Lack of monkeypox virus (MPXV) transmission despite occupational exposure of a large number of health care workers.

40. Training in infectious diseases across Europe in 2021 – a survey on training delivery, content and assessment

42. Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1

43. Safety and antiviral activity of combination HIV-1 broadly neutralizing antibodies in viremic individuals

44. Combination therapy with anti-HIV-1 antibodies maintains viral suppression

45. HIV therapeutic vaccine enhances non-exhausted CD4+ T cells in a randomised phase 2 trial

46. Comparison of the Outcomes of Individuals With Medically Attended Influenza A and B Virus Infections Enrolled in 2 International Cohort Studies Over a 6-Year Period: 2009–2015

47. Antibody 10-1074 suppresses viremia in HIV-1-infected individuals

48. The “Choosing Wisely” initiative in infectious diseases

Catalog

Books, media, physical & digital resources